ClinicalTrials.gg
CompletedNCT04849988Updated Feb 14, 2024Results posted

A Phase 2 Study to Evaluate the Safety and Efficacy of ABP-450 in the Treatment of Cervical Dystonia

A Phase 2 interventional study of ABP-450 and Placebo in Cervical Dystonia, sponsored by AEON Biopharma, Inc.. Completed at 21 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-02-14.

Sponsored by AEON Biopharma, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
61
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 57 studies in Torticollis with a site in United States — 7 open to participants now, 8 under way, none of them phase 3. Torticollis · United States.

Enrollment
15th of 38
61 · median 45
Started
2021
with 3 others
Phase 2
10 of 57
4 open now
Registered
44th of 57
by date
Lead sponsor
2 of 57
AEON Biopharma, Inc.

Among the 57 studies in Torticollis with a site in United States, this one is the 15th largest by enrollment of the 38 interventional ones that give a count, is one of 4 that started in 2021, is one of 10 in phase 2, and was the 44th registered.

Torticollis

121 studies on the registry are indexed under Torticollis; 18 are open to participants now.

Browse Torticollis studies →

Open to participants now

7 of the 57 studies in Torticollis with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Torticollis studies recruiting now, 4 (33%) set no upper age limit and 4 (33%) stop at 75 or younger; 2 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Torticollis with a site in United States, or all of them as a file.
02

Study summary

This Phase 2 trial will evaluate the safety and efficacy of ABP-450 for the treatment of cervical dystonia in adults. The study will enroll 60 patients across approximately 30 sites in the United States. Study subjects will be divided evenly across a low dose group, a medium dose group, a high dose group, and a placebo group for one treatment cycle.

Read the detailed description

This Phase 2 trial will evaluate the safety and efficacy of ABP-450 for the treatment of cervical dystonia in adults. The study will enroll 60 patients across approximately 30 sites in the United States. Study subjects will be divided evenly across a low dose, a medium dose group, a high dose and placebo group for one treatment cycle.

03

Conditions studied

  • Cervical Dystonia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients between 18 and 75 years of age (inclusive)
  2. A clinical diagnosis of cervical dystonia (ie, spasmodic torticollis) defined by:

    • TWSTRS total score ≥20
    • TWSTRS severity score ≥10
    • TWSTRS disability score ≥3
    • TWSTRS pain score ≥1
  3. On a stable dose of medications (if any) used for focal dystonia treatment (eg, anticholinergics and benzodiazepines) for at least 3 months prior to and expected throughout the study duration
  4. For pre-treated patients only: Source documentation (eg, patient history) of the last 2 consecutive injection sessions with a botulinum toxin type A
  5. For pre-treated patients only: At least 16 weeks must have passed between the last injection with botulinum toxin for cervical dystonia and baseline treatment (patients can be screened at Week 15 but cannot be enrolled until 16 weeks [for Day 0 injection])
  6. Provided written to being treated for cervical dystonia with ABP-450
  7. Stated willingness to comply with all study procedures, including attendance at the study center for all study visits as scheduled and have technological capabilities to have televisits

Exclusion criteria

Exclusion Criteria:

  1. Traumatic torticollis or tardive torticollis
  2. Predominant retrocollis or anterocollis
  3. Myotomy or denervation surgery in the affected muscles (eg, peripheral denervation and/or spinal cord stimulation)
  4. to human serum albumin, sucrose, or botulinum toxin type A
  5. Previous treatment for cervical dystonia with rimabotulinumtoxin B
  6. Diagnosis of myasthenia gravis, Lambert-Eaton syndrome, amyotrophic lateral sclerosis, or any other significant neuromuscular disease that might interfere with the trial
  7. Current swallowing disorder of any origin (dysphagia scale ≥3, ie, severe, with swallowing difficulties and requiring a change in diet)
  8. Marked limitation on passive range of motion that suggests contractures or other structural abnormality, eg, cervical contractures or cervical spine syndrome
  9. Treatment with botulinum toxins of any type for any indication other than cervical dystonia within 16 weeks prior to baseline and during the study
  10. Medical or psychiatric conditions that may increase the risk associated with study participation or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study
  11. Participation in another interventional study during participation in this study
  12. Pregnant or lactating females, or females of not willing to use an acceptable method of (ie, intrauterine device, barrier methods with spermicide, or abstinence)
  13. For pre-treated patients only: The patient's most recent injection with botulinum toxin exceeding the number of units specified as follows:

    • OnabotulinumtoxinA (BOTOX®): >300 units
    • IncobotulinumtoxinA (Xeomin®): >300 units
    • AbobotulinumtoxinA (Dysport®): >750 units
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    ABP-450 - Low Dose

    ABP-450 Low Dose - Intramuscular injections into affected neck muscles.

    Drug: ABP-450

  • Experimental
    ABP-450 - Medium Dose

    ABP-450 Mid Dose - Intramuscular injections into affected neck muscles.

    Drug: ABP-450

  • Experimental
    ABP-450 - High Dose

    ABP-450 High Dose - Intramuscular injections into affected neck muscles.

    Drug: ABP-450

  • Placebo comparator
    Placebo

    Placebo (0.9% saline, sterile, unpreserved, USP/Ph.Eur.) - Intramuscular injections into affected neck muscles.

    Drug: Placebo

Interventions

  • ABP-450 (prabotulinumtoxinA) contains a 900kDA botulinum toxin type-A complex produced by the bacterium Clostridium botulinum.

    Also known as: prabotulinumtoxinA

  • DrugPlacebo

    0.9% sodium chloride, sterile, unpreserved, USP/Ph.Eur.

    Also known as: 0.9% sodium chloride, saline

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Related Serious Adverse Events

    The primary safety endpoint will be the number of participants with treatment-related serious adverse events since the start of treatment by Treatment Group when dosed with placebo, ABP-450 (low dose), ABP-450 (medium d dose), or ABP-450 (high dose).

    Time frame: Baseline up to 20 Weeks

Secondary outcomes

  1. Mean Change of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)-Total Score From Baseline to Week 4

    The Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) scale is used to assess the severity of cervical Dystonia. The TWSTRS-total score has a minimum score of 0 and a maximum score of 85, where higher scores represent worse outcomes. It comprises 3 subscales, which are summated to get the total score: the Torticollis Severity Scale (minimum score of 0, maximum score of 35), the Disability Scale (minimum score of 0, maximum score of 30), and the Pain Scale (minimum score of 0, maximum score of 20).

    Time frame: Baseline to Week 4

  2. Mean Change in the Subscale Score of Disability of the Baseline Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) From Baseline to Week 4

    The Disability subscale of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) is used to assess the severity of disability in cervical dystonia. The disability subscale has a minimum score of 0 and maximum score of 30, where higher scores represent worse outcomes.

    Time frame: Baseline to Week 4

  3. Mean Change in the Subscale Score of Pain of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) From Baseline to Week 4

    The Pain subscale of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) is used to assess the severity of pain in cervical dystonia. The pain subscale has a minimum score of 0 and maximum score of 20, where higher scores represent worse outcomes.

    Time frame: Baseline to Week 4

  4. Mean Change in the Subscale Score of Severity of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) From Baseline to Week 4

    The Severity subscale of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) is used to assess the severity of torticollis in cervical dystonia. The severity subscale has a minimum score of 0 and maximum score of 35, where higher scores represent worse outcomes.

    Time frame: Baseline to Week 4

  5. Mean Change in Patient Global Impression of Change (PGI-C) From Baseline to Week 4

    The PGI-C enables the patient to rate changes in their perception of their general health status over the duration of the assessment via a 7-point scale ranging from "much improved" to "much worse". The 7-point scale range is much improved (+3) to much worse (-3) with no change at "0". The mean change in the subject's assessment of the change in clinical status since the start of treatment measured by the Patients' Global Impression of Change (PGI-C) Scale was assessed by Treatment Group at Week 4.

    Time frame: Baseline to Week 4

  6. Mean Change in Clinical Global Impression of Change (CGI-C) From Baseline to Week 4

    The CGI-C enables the patient to rate changes in their perception of their general health status over the duration of the assessment via a 7-point scale ranging from "much improved" to "much worse". The 7-point scale range is much improved (+3) to much worse (-3) with no change at "0". The mean change from Baseline in the Clinical Global Impression of Change (CGI-C) Score was assessed by Treatment Group at Week 4.

    Time frame: Baseline to Week 4

07

Results

Posted Feb 14, 2024

Participant flow

Participants were recruited at 25 sites in the U.S. between March 29, 2021 and July 11, 2021.

Participant flow — Overall Study
MilestonePlaceboABP-450 - 150UABP-450 - 250UABP-450 - 350U
Started15151615
Randomized but not dosed1100
Treated14141615
Safety analysis set14141615
Full analysis set14141615
Modified full analysis set14141415
Completed1191310
Not completed4635
Withdrew: Lack of efficacy3414
Withdrew: Other reasons1221

Outcome measures

PrimaryNumber of Participants With Treatment-Related Serious Adverse Events

The primary safety endpoint will be the number of participants with treatment-related serious adverse events since the start of treatment by Treatment Group when dosed with placebo, ABP-450 (low dose), ABP-450 (medium d dose), or ABP-450 (high dose).

Time frame:
Baseline up to 20 Weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Related Serious Adverse Events
ParticipantsPlaceboABP-450 - 150UABP-450 - 250UABP-450 - 350U
Number of Participants With Treatment-Related Serious Adverse Events0000
SecondaryMean Change of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)-Total Score From Baseline to Week 4

The Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) scale is used to assess the severity of cervical Dystonia. The TWSTRS-total score has a minimum score of 0 and a maximum score of 85, where higher scores represent worse outcomes. It comprises 3 subscales, which are summated to get the total score: the Torticollis Severity Scale (minimum score of 0, maximum score of 35), the Disability Scale (minimum score of 0, maximum score of 30), and the Pain Scale (minimum score of 0, maximum score of 20).

Time frame:
Baseline to Week 4
Reported as:
Least squares mean · score on a scale
Mean Change of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)-Total Score From Baseline to Week 4
score on a scalePlaceboABP-450 - 150UABP-450 - 250UABP-450 - 350U
Mean Change of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)-Total Score From Baseline to Week 43.57 ± 2.6714.01 ± 2.6311.28 ± 2.709.92 ± 2.54
SecondaryMean Change in the Subscale Score of Disability of the Baseline Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) From Baseline to Week 4

The Disability subscale of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) is used to assess the severity of disability in cervical dystonia. The disability subscale has a minimum score of 0 and maximum score of 30, where higher scores represent worse outcomes.

Time frame:
Baseline to Week 4
Reported as:
Least squares mean · score on a scale
Mean Change in the Subscale Score of Disability of the Baseline Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) From Baseline to Week 4
score on a scalePlaceboABP-450 - 150UABP-450 - 250UABP-450 - 350U
Mean Change in the Subscale Score of Disability of the Baseline Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) From Baseline to Week 41.02 ± 1.114.53 ± 1.094.24 ± 1.142.62 ± 1.06
SecondaryMean Change in the Subscale Score of Pain of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) From Baseline to Week 4

The Pain subscale of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) is used to assess the severity of pain in cervical dystonia. The pain subscale has a minimum score of 0 and maximum score of 20, where higher scores represent worse outcomes.

Time frame:
Baseline to Week 4
Reported as:
Least squares mean · score on a scale
Mean Change in the Subscale Score of Pain of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) From Baseline to Week 4
score on a scalePlaceboABP-450 - 150UABP-450 - 250UABP-450 - 350U
Mean Change in the Subscale Score of Pain of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) From Baseline to Week 41.27 ± 1.103.56 ± 1.053.58 ± 1.083.69 ± 1.02
SecondaryMean Change in the Subscale Score of Severity of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) From Baseline to Week 4

The Severity subscale of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) is used to assess the severity of torticollis in cervical dystonia. The severity subscale has a minimum score of 0 and maximum score of 35, where higher scores represent worse outcomes.

Time frame:
Baseline to Week 4
Reported as:
Least squares mean · score on a scale
Mean Change in the Subscale Score of Severity of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) From Baseline to Week 4
score on a scalePlaceboABP-450 - 150UABP-450 - 250UABP-450 - 350U
Mean Change in the Subscale Score of Severity of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) From Baseline to Week 41.91 ± 0.915.89 ± 0.912.94 ± 0.973.45 ± 0.87
SecondaryMean Change in Patient Global Impression of Change (PGI-C) From Baseline to Week 4

The PGI-C enables the patient to rate changes in their perception of their general health status over the duration of the assessment via a 7-point scale ranging from "much improved" to "much worse". The 7-point scale range is much improved (+3) to much worse (-3) with no change at "0". The mean change in the subject's assessment of the change in clinical status since the start of treatment measured by the Patients' Global Impression of Change (PGI-C) Scale was assessed by Treatment Group at Week 4.

Time frame:
Baseline to Week 4
Reported as:
Least squares mean · units on a scale
Mean Change in Patient Global Impression of Change (PGI-C) From Baseline to Week 4
units on a scalePlaceboABP-450 - 150UABP-450 - 250UABP-450 - 350U
Mean Change in Patient Global Impression of Change (PGI-C) From Baseline to Week 44.0 ± 1.112.6 ± 0.312.2 ± 0.322.7 ± 0.30
SecondaryMean Change in Clinical Global Impression of Change (CGI-C) From Baseline to Week 4

The CGI-C enables the patient to rate changes in their perception of their general health status over the duration of the assessment via a 7-point scale ranging from "much improved" to "much worse". The 7-point scale range is much improved (+3) to much worse (-3) with no change at "0". The mean change from Baseline in the Clinical Global Impression of Change (CGI-C) Score was assessed by Treatment Group at Week 4.

Time frame:
Baseline to Week 4
Reported as:
Least squares mean · units on a scale
Mean Change in Clinical Global Impression of Change (CGI-C) From Baseline to Week 4
units on a scalePlaceboABP-450 - 150UABP-450 - 250UABP-450 - 350U
Mean Change in Clinical Global Impression of Change (CGI-C) From Baseline to Week 43.9 ± 0.332.3 ± 0.322.0 ± 0.332.7 ± 0.31

Adverse events

Collected over Up to Week 20. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/14 (0%)0/14 (0%)9/14 (64.3%)
ABP-450 - 150U0/14 (0%)0/14 (0%)8/14 (57.1%)
ABP-450 - 250U0/16 (0%)0/16 (0%)12/16 (75%)
ABP-450 - 350U0/15 (0%)0/15 (0%)11/15 (73.3%)
Most frequent other events
Showing 10 of 22
Most frequent other events
EventPlaceboABP-450 - 150UABP-450 - 250UABP-450 - 350U
Neck painMusculoskeletal and connective tissue disorders3/141/142/161/15
DysphagiaGastrointestinal disorders0/140/142/163/15
Muscular WeaknessGastrointestinal disorders0/142/141/161/15
HeadacheNervous system disorders1/142/142/161/15
TorticollisMusculoskeletal and connective tissue disorders0/140/141/162/15
COVID-19Infections and infestations0/141/141/162/15
NauseaGastrointestinal disorders0/140/142/160/15
Upper respiratory tract infectionInfections and infestations0/140/142/160/15
Head discomfortNervous system disorders0/141/140/160/15
Injection site painGeneral disorders1/141/140/160/15

Baseline characteristics

Two patients were excluded from the analysis due to a change in their background medication.

Age, Continuous
Age, Continuous(years)PlaceboABP-450 - 150UABP-450 - 250UABP-450 - 350UTotal
Mean59.3 ± 11.0655.8 ± 12.9754.6 ± 13.6155.3 ± 11.3956.2 ± 12.09
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboABP-450 - 150UABP-450 - 250UABP-450 - 350UTotal
Female77131239
Male771318
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboABP-450 - 150UABP-450 - 250UABP-450 - 350UTotal
American Indian or Alaska Native00000
Asian00101
Native Hawaiian or Other Pacific Islander00000
Black or African American00202
White1314111452
More than one race00000
Unknown or Not Reported10012
Previous treatment with BOTOX®
Previous treatment with BOTOX®(Participants)PlaceboABP-450 - 150UABP-450 - 250UABP-450 - 350UTotal
Count of participants109111040
Duration of Cervical Dystonia
Duration of Cervical Dystonia(years)PlaceboABP-450 - 150UABP-450 - 250UABP-450 - 350UTotal
Mean14.83 ± 11.13414.58 ± 10.7997.36 ± 6.46411.53 ± 7.17512.26 ± 9.421
Baseline TWSTRS-Total Score
Baseline TWSTRS-Total Score(units on a scale)PlaceboABP-450 - 150UABP-450 - 250UABP-450 - 350UTotal
Mean39.68 ± 7.52544.30 ± 6.09342.20 ± 11.58543.62 ± 9.84742.47 ± 8.962
08

Study locations

21 sites
  • Arizona Neuroscience Research
    Phoenix, Arizona 85032, United States
  • Movement Disorder Center of Arizona
    Scottsdale, Arizona 85258, United States
  • Parkinson's and Movement Disorder Institute
    Fountain Valley, California 92708, United States
  • Neuro Pain Medical Center
    Fresno, California 93710, United States
  • Loma Linda University
    Loma Linda, California 92354, United States
  • New England Institute for Neurology and Headache
    Stamford, Connecticut 06905, United States
  • Infinity Clinical Research LLC
    Hollywood, Florida 33024, United States
  • The Neurology Research Group
    Miami, Florida 33176, United States
  • University of South Florida
    Tampa, Florida 33613, United States
  • Neurology One
    Winter Park, Florida 32792, United States
  • Emory University
    Atlanta, Georgia 30329, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Michigan State University
    East Lansing, Michigan 48824, United States
  • Quest Research Institute - Hunt - PPDS
    Farmington Hills, Michigan 48334, United States
  • University of New Mexico
    Albuquerque, New Mexico 87106, United States
  • The Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Cleveland Clinic Lou Ruvo Center for Brain Health
    Cleveland, Ohio 89106, United States
  • The Orthopedic Foundation
    New Albany, Ohio 43054, United States
  • Veracity Neuroscience LLC
    Memphis, Tennessee 38157, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Individual Participant Data collected during the trial, after deidentification may be shared following review of the clinical study report by the FDA review division and if a decision is made to publish the results in a publication outside posting the results in clinicaltrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2021 to primary completion in Jul 2022, 15 months.

Results were first posted in Feb 2024, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2021
First posted
Apr 20, 2021
StartActual
Mar 29, 2021
Primary completionActual
Jul 11, 2022
CompletionActual
Jul 11, 2022
Results first posted
Feb 14, 2024
Last update
Feb 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04849988
Lead sponsor
AEON Biopharma, Inc.
Collaborators
PPD DEVELOPMENT, LP
Responsible party
Sponsor
First posted
Apr 20, 2021
Start date
Mar 29, 2021
Primary completion
Jul 11, 2022
Completion
Jul 11, 2022
Results posted
Feb 14, 2024
Last update
Feb 14, 2024

Study contacts

Cynthia Comella, MD
principal investigator · Rush University Medical Center
Joseph Jankovic
principal investigator · Baylor St. Luke's Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Prabotulinumtoxin A

Start the discussion